6846.TWO Greenyn Biotechnology Co., Ltd
- Market cap
- TWD 1.33B
- P/E
- 12.2x
- P/B
- 1.63x
- ROE
- 10.0%
- Dividend yield
- 7.32%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6846.TWO undervalued?
Graham number6846.TWO trades 6.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Greenyn Biotechnology Co., Ltd fundamental analysis
No fundamental analysis for Greenyn Biotechnology Co., Ltd yet.
Greenyn Biotechnology Co., Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Greenyn Biotechnology Co., Ltd
Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink. It also provides functional formulas for youth and beauty series, digestive health series, brain health series, body regulation series, throat moistening series, hair care se…
Full company profileGreenyn Biotechnology Co., Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Greenyn Biotechnology Co., Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 694M | 705M | 801M | 873M | 915M | 788M |
| Gross Profit | 358M | 371M | 392M | 415M | 440M | 373M |
| Operating Income | 169M | 167M | 161M | 168M | 189M | 122M |
| EBITDA | - | 210M | 192M | 216M | 232M | 181M |
| Net Income | 133M | 147M | 131M | 146M | 146M | 92.1M |
| EPS | 5.44 | 6.01 | 4.87 | 5.41 | 5.38 | 3.40 |
| Balance Sheet | ||||||
| Total Assets | 845M | 835M | 1.16B | 1.11B | 2.11B | 2.47B |
| Total Liabilities | 231M | 273M | 364M | 257M | 1.13B | 1.55B |
| Shareholders' Equity | 614M | 562M | 797M | 851M | 979M | 918M |
| Cash & Short-term Investments | 356M | 370M | 534M | 552M | 793M | 684M |
| Cash Flow | ||||||
| Operating Cash Flow | 81.8M | 230M | 127M | 220M | 159M | 96.6M |
| Capital Expenditure | 17.7M | 17.1M | 89.4M | 9.78M | 395M | 662M |
| Free Cash Flow | 64.1M | 213M | 37.7M | 210M | -236M | -565M |
| Ratios | ||||||
| ROE | 21.6% | 26.1% | 16.4% | 17.1% | 14.9% | 10.0% |
| ROA | 15.7% | 17.6% | 11.3% | 13.2% | 6.9% | 3.7% |
| Net Profit Margin | 19.1% | 20.8% | 16.3% | 16.7% | 15.9% | 11.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Greenyn Biotechnology Co., Ltd dividends
- Dividend yield
- 7.32%
- Forward dividend
- 3.94 TWD
- Payout ratio
- 66.8%
- Ex-dividend date
- Jun 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 97.1M | 3.59 | 66.8% |
| 2024 | TWD 93.9M | 3.48 | 64.3% |
| 2023 | TWD 95.2M | 3.55 | 72.9% |
| 2022 | TWD 200M | 8.20 | 136.4% |
| 2021 | TWD 48.3M | 1.98 | 36.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Greenyn Biotechnology Co., Ltd
- Insiders 71.61%
- Institutions 0.00%
- Public & others 28.39%
- Shares outstanding 27.1M
Greenyn Biotechnology Co., Ltd company profile
- Company name
- Greenyn Biotechnology Co., Ltd
- Ticker
- 6846.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 43, Keya Road, Taichung, Taiwan, 428
- Phone
- 886 4 2238 2860
- Website
- greenynbio.com
About Greenyn Biotechnology Co., Ltd
Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink. It also provides functional formulas for youth and beauty series, digestive health series, brain health series, body regulation series, throat moistening series, hair care series, clear eye series, colorful lifestyle series, joint health series, nutritional supplement series, energy supplement series, immune modulation series, low burden series, sleep aid series, body curve series, circulation series, man power series, women's intimate health series, and mature woman series. In addition, the company offers customization, ODM, dosage, and application services. Greenyn Biotechnology Co., Ltd was founded in 2012 and is based in Taichung, Taiwan.
Greenyn Biotechnology Co., Ltd management
2- Mr. Bang-Kui XuPresident, GM, Head of Sales Departments 1 & 2 & Director
- Mr. Yan-Qin HuangVice Chairman & VP of Operations